Embody
  • Get Started
  • Our Top Products
  • GLP-1 Science
  • What To Expect
  • Market Leading Cost
  • FAQ
  • Contact Us

Accessibility Statement

Last updated: 2026-09-15

Embody is committed to making thepeptidestacks.com accessible to the widest possible audience, including people with disabilities. This statement describes the conformance target we work toward, the measures we take, the limitations we are aware of, and how to reach us about an accessibility barrier.

Conformance Status

The Web Content Accessibility Guidelines (WCAG) define requirements for making web content more accessible to people with disabilities. thepeptidestacks.com aims to conform to WCAG 2.1 Level AA.

thepeptidestacks.com is partially conformant with WCAG 2.1 Level AA. Partially conformant means that some parts of the content do not fully conform to the accessibility standard. We have not published a completed third-party evaluation of the site, and this statement is not a certification of conformance.

Measures We Take

Embody takes the following measures to support accessibility:

  • Building pages from semantic HTML with headings, landmarks, lists, and labelled form controls, so screen readers and other assistive technologies can convey page structure.
  • Supporting keyboard-only operation of navigation, menus, forms, and interactive controls, with a visible focus indicator on focusable elements.
  • Checking text and interface colors for the WCAG AA contrast minimums, including on brand color choices.
  • Providing text alternatives for meaningful images and marking decorative images so assistive technology can skip them.
  • Designing layouts that reflow for small screens, zoom, and increased text size without loss of content or functionality.
  • Reviewing accessibility when we change site content, navigation, forms, and product information, rather than only at launch.

Known Limitations

Despite our efforts, some limitations remain. Below is a description of known limitations. Please contact us if you encounter a barrier that is not listed.

  • Third-party content. Embedded content, payment and scheduling widgets, and other services operated by third parties are not fully under our control, and their accessibility may differ from the rest of the site.
  • Documents and media. Uploaded documents, images of text, and video or audio published by the brand may lack text alternatives, captions, or transcripts.
  • Recently published content. New or updated pages may not yet have completed our accessibility review.

Feedback and Contact

We welcome your feedback on the accessibility of thepeptidestacks.com. If you encounter an accessibility barrier, or need information from this site in a different format, contact us at support@bloome.health or through our contact page.

Please include the page address, a description of the problem, and the browser and assistive technology you were using, if relevant. We aim to respond to accessibility feedback within 5 business days, and we will work with you to provide the information or functionality you need in an accessible form.

Assessment Approach

Embody assesses the accessibility of thepeptidestacks.com by self-evaluation, carried out internally as part of design and content review. This statement is reviewed as the site changes.

Embody
  • 1811 Silverside Road, Suite 260, Wilmington, DE 19180
  • Login

*The assessment made available on the Embody website does not create a doctor-patient relationship between the individual completing the assessment and Embody. Our affiliated network of independent, US-licensed providers, who adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the Embody assessment consequently determine if the individual is screened out of eligibility for GLP-1 medication, and a licensed clinician will meet with an individual after checkout to determine if they qualify for a prescription. Licensed clinicians retain the decision to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and medical history.

We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Embody does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers
We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Embody patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

Medication is included in the cost of the Embody Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, and trade names (Wegovy®, Ozempic®) displayed on this website are protected and belong to their respective owners. Medical treatment is provided by independent licensed providers. No data, photos, claims or any other information is associated with results derived from clinical trials, studies or public information and is always representative of Embody patient experience.

Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content. Individuals appearing in advertisements may be actors or models.

Testimonials on the website are from Embody patients. For patient privacy, images representing those testimonials may use models.

By accepting our Terms of Use, you additionally understand and agree that Embody is not acting as a pharmacy, nor does Embody control or interfere with any such services. By accepting these Terms of Use, you understand and agree that you may be entering into a relationship with a pharmacy, pharmacist, and/or pharmacy group or other such relationship with any one or more such third-party entities. Prescriptions, if issued, are filled by licensed partner pharmacies.

Partner Pharmacies

© 2026 Embody. All rights reserved.

Terms & ConditionsPrivacy PolicyPrivacy PracticesRefund PolicyMedical ConsentFor California ResidentsBill of RightsSafety & Side EffectsTCPA Compliance Policy